CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Effective Date **11/15/2009**
Next Review Date **11/15/2010**
Coverage Policy Number **0235**

Subject Actinic Keratosis Treatments

Table of Contents

Coverage Policy 1
General Background 2
Coding/Billing Information 4
References 5
Policy History... 10

Hyperlink to Related Coverage Policies

Acne Procedures
Benign Skin Lesion Removal
Photodynamic Therapy for Dermatologic Conditions
Phototherapy, Photochemotherapy and Excimer Laser Therapy for Dermatologic Conditions

INSTRUCTIONS FOR USE
*Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2009 CIGNA*

Coverage Policy

CIGNA covers the following treatments for actinic keratosis (AK) as medically necessary:

- cryotherapy
- topical medications[†]
- laser therapy
- photodynamic therapy[††] (PDT) with 5-aminolevulinic acid (5-ALA) and exposure to blue light for the treatment of nonhyperkeratotic AK lesions
- electrodessication and curettage or full-thickness excision when EITHER of the following criteria is met:
  - Progression to squamous cell carcinoma (SCC) is suspected.
  - There has been failure, intolerance or contraindication to treatment using conventional methods (e.g., cryotherapy, topical medication, laser therapy, and/or PDT).
- medium-depth chemical peels, deep chemical peels, or dermabrasion when BOTH of the following criteria are met:
  - There are $\geq$ 10 AK lesions or severe diffuse AK lesions present.

- There has been failure, intolerance or contraindication to treatment using conventional methods (e.g., cryotherapy, topical medication, or electrodessication and curettage).

[†]Note: Coverage of medications related to the treatment of actinic keratosis is subject to the pharmacy benefit portion of the applicable benefit plan.

[††]Note: Please refer to the CIGNA Medical Coverage Policy: Photodynamic Therapy for Dermatologic Conditions.

General Background

Actinic keratoses (AKs) are precancerous skin lesions that occur on the epidermis (outer layer of skin) and may result from long-term exposure to the sun. The condition is also commonly referred to as solar keratosis, senile keratosis, senile hyperkeratosis, keratoma senile and keratosis senilis. Microscopically, AK lesions show varying degrees of atypia and abnormal maturation. AKs are the most commonly treated type of premalignant lesion.

Although AK lesions are frequently asymptomatic, some exhibit signs and symptoms such as thickening, burning, itching or tenderness at the site. Lesions may vary in size from 3–10 mm in diameter and enlarge gradually. Actinic keratosis may present as a single lesion or multiple lesions on sun-exposed areas of the skin. The lesions are usually poorly demarcated, appearing as slightly erythematous papules or plaques in areas such as the face, balding scalp, posterior neck, upper chest and dorsal upper extremity. They often appear reddish in color with a white scale on top. The lesions may be difficult to see; they may feel scaly or crusted on palpation, and are better examined under intense lighting.

Although most AKs can be treated effectively, in a small number of cases these lesions have the potential to develop into squamous cell carcinomas after several years. The likelihood of an AK developing into a squamous cell carcinoma is estimated at 0.085% per lesion per year (Habif, 2004), although the estimated risk varies among sources. Up to 60% of squamous cell carcinomas develop from AKs and, while not usually aggressive, SCCs may eventually metastasize.

Current treatments focus on destroying the AKs, as no method can reliably predict if and when malignancy will develop. Lesions located on the lip, eye and ear typically are at high risk of developing into squamous cell carcinoma when left untreated, however not all AKs need to be treated. One alternative approach is to observe the lesions over time and remove them if they exhibit clinical features indicating disease progression. Nonetheless, it is impossible to distinguish between an AK lesion and SCC, so treatment should be aggressive to stop the progression to SCC (Berman, et al., 2006; Habif, 2004).

Choosing among the various treatment options depends on the lesion's size, anatomical location, changes in growth pattern, and extent; previous treatment; and the patient's medical history and treatment preference (Drake, et al, 1995; Helfand, et al., 2001). Conventional treatment methods include cryotherapy, topical medications, and laser therapy. Electrodessication and curettage, chemical peels, and dermabrasion are used less frequently but have proven effective. More recently, photodynamic therapy (PDT) and the topical application of the immunomodulator, Aldara (imiquimod), have been shown to improve patient outcomes. The persistence of a lesion after treatment is suspicious and may warrant a biopsy or full excision of the lesion.

Treatment Options

Cryotherapy: The most effective and practical method of treating isolated AKs, cryotherapy, is used when AK lesions are either very few in number and small in size or multiple and scattered. Liquid nitrogen, applied directly, destroys the lesion. This method of treatment does not require anesthesia and causes the lesion to slough off, allowing new tissue growth.

Topical Medications: Topical treatments (e.g., medicated creams and solutions) are most often used in cases where multiple superficial AK lesions are present. The most widely used topical treatment is 5-fluorouracil (5–FU), also known as Efudex® (Valeant Pharmaceuticals International, Costa Mesa, CA). Other topical medications currently used in the treatment of multiple AK lesions include Solaraze® Gel (diclofenac sodium gel 3%) and Aldara™ (imiquimod). Solaraze combines nonsteroidal, anti-inflammatory diclofenac sodium

in a 3% gel for topical use. Aldara is an immune response modifier, which, when used topically, will destroy the lesion.

Laser Therapy: Laser therapy employs high-intensity light to treat AK lesions. Various types of lasers may be used, including carbon dioxide, YAG, and pulsed lasers. The laser produces invisible, mid-infrared light that can be used to vaporize superficial cutaneous lesions, allowing resurfacing of the skin. Laser therapy is often recommended to treat AK of the lips (i.e., actinic cheilitis) and diffuse AK lesions.

Photodynamic Therapy (PDT): PDT is a therapy that involves applying a topical solution of 20% 5-aminolevulinic acid to atypical cells, then exposing them to blue light 14–18 hours later in order to photosensitize them. Irradiating the cells with light of an appropriate wavelength, such as that emitted by the BLU–U™ Blue Light Photodynamic Therapy Illuminator (DUSA Pharmaceuticals, Inc.®, Wilmington, MA), causes cell death. Methyl aminolevulinate (MAL) and 5-aminolevulinic acid (ALA) are both topical photosensitizer precursors used in combination with PDT. This therapy is indicated for the treatment of non-hyperkeratotic actinic keratosis of the face or scalp, as well as when more than 10 lesions require treatment. PDT can be used over large surface areas.

Electrodessication and Curettage: Electrodessication and curettage, (i.e., scraping away the affected lesion with a curette), is often performed in conjunction with electrosurgery to inhibit possible bleeding. Because this method allows the tissue to be sent for pathological diagnosis, it is recommended in suspected cases of squamous cell carcinoma, in documented cases of previous resistance to treatments, and after biopsy.

Excision: Excisional removal may be indicated when prior treatments have been unsuccessful or when aggressive progression to squamous cell carcinoma is suspected. Individuals who are immunocompromised, have extremely sun-damaged skin, have had exposure to radiation or other known skin carcinogens, or have xeroderma pigmentosum, albinism, prior exposure to arsenicals or a personal history of skin cancer have been identified as having a high risk of developing squamous cell carcinoma.

Chemical Peels: Although less frequently used than cryosurgery or curettage, medium and deep chemical peels have proven effective in treating AK lesions. This method employs the topical application of chemicals to the skin, causing removal of layers of the epidermis and superficial dermis. These solutions damage the outer layer of skin, causing the skin to blister and peel off in a few days. The peeling off of treated skin stimulates new skin growth, usually within seven days. The most frequently used chemical peels are trichloracetic acid and Jessner's solution. They are reserved for cases where large numbers of AK lesions (more than 10) have been documented, when it is impractical to treat each lesion separately, and where there is a record of conventional methods, including cryotherapy, topical medications and electrodessication and curettage having proved unsuccessful. When used to treat other epidermal or dermal conditions, such as photo-aging, active acne vulgaris, acne scarring, wrinkles or uneven pigmentation, chemical peels are considered cosmetic and not medically necessary.

Dermabrasion: Dermabrasion, also known as surgical skin planing, is a method of removing AK lesions by mechanically removing or "sanding" the skin using a rotary abrasive instrument. Dermabrasion is also often employed to treat wrinkles, acne and uneven pigmentation, although its use for these conditions is cosmetic and not medically necessary. While not used as often as other methods in the treatment of AK lesions, dermabrasion has proven effective in treating AK lesions in cases where numerous AK lesions (e.g., more than 10) have been documented or for severe diffuse AK lesions, when it is impractical to treat each lesion separately, and when conventional methods, including cryotherapy, topical medications and electrodessication and curettage have been tried unsuccessfully.

Literature Review

Evidence in the published scientific literature supports the effectiveness of various treatment options for AK and consist of both retrospective and prospective case series, randomized controlled trials, comparative trials and published reviews (Kaminaka, et al., 2009; Zeichner, et al., 2009; Kaufmann, et al., 2008; Kose, et al., 2008; Jorizzo, et al., 2007a; Braathen, et al., 2007; Moloney and Collins, 2007; Sherry, et al., 2007; Smith, et al., 2006; Morton, et al., 2006; Tschen, et al., 2006; Smith, et al., 2006; Lebwohl, et al., 2004; Thai, et al., 2004; Kurwa, et al., 1999; Whitheiler, et al., 1997; Lawrence, et al., 1995). Although few studies compare treatments to determine which provides the best outcomes, overall, the available therapies are proven to be safe, effective and well-tolerated.

Professional Societies/Organizations
Guidelines were issued by the National Comprehensive Cancer Network (NCCN) for basal and squamous cell skin cancers. As part of the identification and management of high risk patients the NCCN recommends aggressive treatment of AK at first development. In reference to treatments, the accepted treatment modalities include cryosurgery, topical 5-flourourical, topical imiquimod, photo-dynamic therapy, and curettage and electrodessication. Other modalities that may be considered include chemical peels (trichloracetic acid), and ablative skin resurfacing (laser, dermabrasion). Actinic keratosis that has an atypical clinical appearance or that do not respond to appropriate therapy should be biopsied for histologic evaluation" (NCCN, 2009).

Summary
Evidence in the published scientific literature suggests that a number of treatment modalities for actinic keratoses (AK) are safe and effective; however, few studies compare treatments to determine which provide the best outcomes. Authors agree that the method of treatment selected depends on several variables and that different methods of treatment may be necessary for different clinical cases. Since AKs have been classified as premalignant lesions, meaning that some lesions may progress to invasive squamous carcinoma, treatment of these lesions is considered medically necessary as it will ultimately help prevent future development of invasive squamous cell carcinoma.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Covered when medically necessary:

CPT®* Codes	Description
11400	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less
11401	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.6 to 1.0 cm
11402	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 1.1 to 2.0 cm
11403	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm
11404	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 3.1 to 4.0 cm
11406	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter over 4.0 cm
11420	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less
11421	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm
11422	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm
11423	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm
11424	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm
11426	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm
11440	Excision, other benign lesion including margins (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.5 cm or less
11441	Excision, other benign lesion including margins (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.6 to 1.0 cm
11442	Excision, other benign lesion including margins (unless listed elsewhere), face,

	ears, eyelids, nose, lips, mucous membrane; excised diameter 1.1 to 2.0 cm
11443	Excision, other benign lesion including margins (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 2.1 to 3.0 cm
11444	Excision, other benign lesion including margins (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 3.1 to 4.0 cm
11446	Excision, other benign lesion including margins (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter over 4.0 cm
15781	Dermabrasion; segmental, face
15782	Dermabrasion; regional, other than face
15789	Chemical peel, facial; dermal
15793	Chemical peel, nonfacial; dermal
17000	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), all benign or premalignant lesions (eg, actinic keratoses) other than skin tags or cutaneous vascular proliferative lesions; first lesion
17003	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), all benign or premalignant lesions (eg, actinic keratoses) other than skin tags or cutaneous vascular proliferative lesions; second through 14 lesions, each (List separately in addition to code for first lesion)
17004	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), all benign or premalignant lesions (eg, actinic keratoses) other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions
96567	Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (eg, lip) by activation of photosensitive drug(s), each phototherapy exposure session

HCPCS Codes	**Description**
J7308	Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg)

ICD-9-CM Diagnosis Codes	**Description**
702.0	Actinic keratosis

***Current Procedural Terminology (CPT®) ©2008 American Medical Association: Chicago, IL.**

References

1. Actinic keratosis. In: Habif T. Clinical Dermatology, 4th ed. St. Louis, MO: Mosby-Yearbook, Inc.; 2004. p. 736-43.

2. Actinic Keratosis Net. In the spotlight. Updated 8/04/06. © American Academy of Dermatology, 2005. Accessed September 11, 2009. Available at URL address: http://www.skincarephysicians.com/actinickeratosesnet/index.html

3. Aldara Cream 5%. 3M Pharmaceuticals. Northridge, California. Accessed September 11, 2006. Available at URL address: http://www.3m.com/us/healthcare/pharma/aldara/AldaraPI.pdf

4. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol. 2006 Jan-Feb;24(1):16-25.

5. American Academy of Dermatology. Position statement. Actinic keratosis. 2003. Accessed Oct, 2005. Available at URL address: http://www.aadassociation.org/Policy/ak.html

6. American Academy of Dermatology. Practice management. Guidelines of care for actinic keratosis. 2003. Accessed October 6, 2005. Available at URL address: http://www.aadassociation.org/Guidelines/actkeratoses.html

7. American Academy of Dermatology. Fact Sheet: Actinic keratosis and skin cancer. Copyright © 2006 American Academy of Dermatology. Accessed October 11, 2007. Available at URL address: http://www.aad.org/public/News/DermInfo/ActKerSkCancFAQ.htm

8. American Cancer Society. Detailed guide: Skin cancer: Basal and Squamous Cell. Chemotherapy. Revised 06/10/2008. Accessed September 11, 2009. Available at URL address: http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Chemotherapy_51.asp?sitearea=

9. American Cancer Society. Detailed guide: skin cancer: nonmelanoma. Treatment of actinic keratosis. Revised 06/10/2008. Accessed September 11, 2009. Available at URL address: http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Treatment_of_Actinic_Keratosis_51.asp?sitearea=CRI

10. American Osteopathic College of Dermatology. Dermatologic disease database. Actinic keratosis. Accessed September 11, 2009. Available at URL address: http://www.aocd.org/skin/dermatologic_diseases/actinic_keratosis.html

11. Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology-an update. Photodermatol Photoimmunol Photomed. 2005 Jun;21(3):142-9.

12. Babilas P, Knobler R, Hummel S, Gottschaller C, Maisch T, Koller M, Landthaler M, Szeimies RM. Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol. 2007 Jul;157(1):111-7. Epub 2007 Jun 2.

13. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008 Jul;7(7):669-73 (abstract only).

14. Berman B, Bienstock L, Kuritzky L, Mayeaux EJ Jr, Tyring SK; Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006 May;55(5):suppl 1-8.

15. Bickers DR; Lim HW; Margolis D; Weinstock MA; Goodman C; Faulkner E; Gould C; Gemmen E; Dall T; American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490-500.

16. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. j Am Acad Dermatol. 2007 Jan;56(1):125-43.

17. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Aced Dermatol. 2005 Dec;53(6):966-72.

18. de Berker D, McGregor JM, Hughes BR, British Association of Dermatologists Therapy Guidelines and Audit. Guidelines for the management of actinic keratoses. Br J Dermatol 2007 Feb;156(2):222-30.

19. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, Graham GF, Lewis CW, Salasche SJ, Turner ML, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995 Jan;32(1):95-8.

20. Ericson MB, Wennberg AM, Larkö O. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag. 2008 Feb;4(1):1-9.

21. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. 2006 Sep;55(3):537-8.

22. Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol. 2006 Sep-Oct;72(5):346-9.

23. Ferrandiz C. Update on actinic keratosis in clinical trial experience with imiquimod. Br J Dermatol. 2007 Dec;157 Suppl 2:32-3.

24. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatologic Treat. 2003 Jun;14(2):99-106.

25. Gupta AK, Inniss K, Wainwright R, Chow M, Cooper E. Interventions for actinic keratoses (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update software. Updated 2004 Jul. Accessed October, 2004. Available at URL address: http://md.skolar.com/index__.jsp?trg=%2Fshine%2Fhome%2Fsearch.jsp%3Fy%3D0%26x%3D0&nav=home

26. Helfand M, Gorman AK, Mahon S, Chan BKS, Swanson N. Actinic keratoses, final report. Submitted to the Agency for Healthcare Research and Quality (AHRQ) under contract 290-97-0018, task order no. 6. Oregon Health & Science University Evidence-Based Practice Center, Portland, OR. Rockville, MD: AHRQ; 2001 May 19. Accessed September 11, 2009. Available at URL address: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=1

27. Hruza GJ. Laser treatment of epidermal and dermal lesions. Dermatol Clin. 2002 Jan;20(1):147-64.

28. Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Derm. 2007b Aug;57(2):265-8.

29. Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002 Dec;70(6):335-9.

30. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006 Feb;5(2):133-9.

31. Kaminaka C, Yamamoto Y, Yonei N, Kishioka A, Kondo T, Furukawa F. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol. 2009 Apr;60(4):615-25.

32. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008 May;158(5):994-9. Epub 2008 Mar 13.

33. Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005 Apr;141(4):467-73.

34. Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat. 2008 Jan;19(3):159-63.

35. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8.

36. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloracetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995 Feb;131(2):176-81.

37. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May; 50(5):714-721.

38. Lewin Group, Inc. The Burden of Skin Diseases: 2004. Prepared for: The Society for Investigative Dermatology and The American Academy of Dermatology Association. Released April 2005. Copyright © 2005 by The Society for Investigative Dermatology and The American Academy of Dermatology Association. Accessed September 11, 2009. Available at URL address: http://www.sidnet.org/Burden_Skin_Disease.asp

39. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002 Jun;24(6):990-1000.

40. McGovern TW, Leffell DJ. Actinic keratoses and non-melanoma skin cancer. American Academy of Dermatology. 2004. Accessed October 6, 2005. Available at URL address: http://www.aad.org/professionals/ResidentMedStudents/MedStudCoreCurr/DCActinicKer-NoMelCancer.htm

41. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. B r J Dermatol. 2007 Jul;157(1):87-91. Epub 2007 May 14.

42. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, Walton S, Kerrouche N, Thomas G, Soto P; AKtion Investigators. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006 Nov;155(5):1029-36.

43. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Basal Cell and Squamous Cell Skin Cancers. Version 1.2009. Accessed September 11, 2009. Available at URL address: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

44. National Institute for Health and Clinical Excellence (NHS). Photodynamic therapy for non-melanoma skin tumours (including pre-malignant and primary non-metastatic skin lesions). Interventional procedure guidance 155. Issued February 2006. Accessed September 11, 2009. Available at URL address: http://guidance.nice.org.uk/IPG155/guidance/pdf/English

45. Ostertag JU, Quaedvlieg PJ, van der Geer S, Nelemans P, Christianen ME, Neumann MH, Krekels GA. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med. 2006 Sep;38(8):731-9.

46. Perras C. Imiquimod 5% cream for actinic keratosis. Issues Emerg Health Technol. 2004 Sep(61):1-4.

47. Piacquadio DJ, Chen DM, Farber HF, Fowler JF Jr., Glazer SD, Goodman JJ, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic

keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004 Jan;140(1):41-6.

48. Radakovic-Fijan S, Blecha-Thalhammer U, Kitler H, Honigsmann H, Tanew A. Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study. J Am Acad Dermatol. 2005 Nov;53(5):823-7.

49. Russo GG. Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin Dermatol. 2005 Nov-Dec;23(6):581-6.

50. Skin Cancer Foundation. Actinic keratosis and other precancers. Accessed September 11, 2009. Available at URL address: http://www.skincancer.org/ak/index.php

51. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006 Feb;5(2):156-9.

52. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003 Dec;2(6):629-35.

53. Somani N, Rivers JK. Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett. 2005 Mar;10(2)1-6.

54. Spencer JM. Actinic keratosis. eMedicine Specialties. Dermatology. Malignant neoplasms. Updated Feb 18, 2009. Accessed September 11, 2009. Available at URL address: http://www.emedicine.com/derm/topic9.htm

55. Stritt A, Merk HF, Braathen LR, von Felbert V. Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol. 2008 Mar;84(2):388-98.

56. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004 Oct;51(4):547-55.

57. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85(5):424-8.

58. Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004 Sep;43(9):687-92.

59. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB; Phase IV ALA-PDT Actinic Keratosis Study Group. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006 Dec;155(6):1262-9.

60. Zeichner JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol. 2009 Jan;60(1):59-62.

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	11/15/2007	0235	Actinic Keratosis Treatments

"CIGNA" and the "Tree of Life" logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.